(Q38241160)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Ferenc Sipos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Zsolt Tulassay

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Bela Molnar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Yukako Yagi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

18 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pathology

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

1026-1031

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25135950%20AND%20SRC:MED&resulttype=core&format=json

Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression.

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Microenvironment-mediated resistance to anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Tumor microenvironment complexity: emerging roles in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Recent developments in myofibroblast biology: paradigms for connective tissue remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Exosomes in tumor microenvironment influence cancer progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Carcinoma-associated fibroblasts are a promising therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Fibroblast-mediated drug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Environment-mediated drug resistance: a major contributor to minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

The multifaceted role of periostin in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Tumor stroma as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

The fibroblast: sentinel cell and local immune modulator in tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Macrophage regulation of tumor responses to anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Influence of tumour micro-environment heterogeneity on therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Fibroblast activation protein: A potential therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

TGF-beta in CAF-mediated tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Complexities of TGF-β targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Cancer-associated fibroblasts as targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

The TGF-beta paradox in human cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

TGF-beta-induced epithelial to mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Role of transforming growth factor Beta in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Molecular pathways: targeting the TGF-β pathway for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Concise drug review: pazopanib and axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

MET: a promising anticancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Cancer associated fibroblasts in cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Insulin-like growth factor 1 mediates 5-fluorouracil chemoresistance in esophageal carcinoma cells through increasing survivin stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Cancer associated fibroblasts (CAFs) in tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Breast-Cancer Stromal Cells withTP53Mutations and Nodal Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561

Clonal Mutations in the Cancer-Associated Fibroblasts: The Case against Genetic Coevolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202561